Beware The Ides of March? AnaptysBio's Imsidolimab Has Another Trial Failure

 
• By Alaric DeArment
  
AnaptysBio may have a better shot at a rarer skin condition with imsidolimab after acne trial failure • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Dermatological

More from Therapeutic Category